IRIS
FACCHINETTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.472
AS - Asia 1.218
EU - Europa 662
SA - Sud America 185
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.426
SG - Singapore 507
CN - Cina 236
VN - Vietnam 192
SE - Svezia 161
IT - Italia 137
BR - Brasile 135
IE - Irlanda 132
HK - Hong Kong 96
BD - Bangladesh 65
DE - Germania 50
FR - Francia 42
ZA - Sudafrica 35
NL - Olanda 31
CA - Canada 28
IN - India 26
GB - Regno Unito 24
AT - Austria 23
TR - Turchia 20
ID - Indonesia 18
RU - Federazione Russa 15
AR - Argentina 13
JP - Giappone 12
MX - Messico 12
EC - Ecuador 11
PL - Polonia 10
CL - Cile 6
PK - Pakistan 6
PY - Paraguay 6
BE - Belgio 5
FI - Finlandia 5
BO - Bolivia 4
CO - Colombia 4
ES - Italia 4
IL - Israele 4
IQ - Iraq 4
PH - Filippine 4
UA - Ucraina 4
AL - Albania 3
KE - Kenya 3
MA - Marocco 3
RO - Romania 3
SA - Arabia Saudita 3
TH - Thailandia 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
CI - Costa d'Avorio 2
GR - Grecia 2
JO - Giordania 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BZ - Belize 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GY - Guiana 1
HN - Honduras 1
IR - Iran 1
IS - Islanda 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
UY - Uruguay 1
ZM - Zambia 1
Totale 3.589
Salva come PNG Salva come JPEG
Città #
Singapore 289
Ashburn 215
Chandler 195
San Jose 136
Dublin 129
Dallas 108
Santa Clara 108
Hong Kong 92
New York 64
Ho Chi Minh City 61
Beijing 57
Shanghai 49
Council Bluffs 48
Boardman 38
Ann Arbor 35
Hanoi 34
Lauterbourg 32
Johannesburg 30
Los Angeles 30
Princeton 23
Bremen 20
Vienna 19
Da Nang 17
Columbus 14
Dearborn 14
Parma 14
Buffalo 13
Des Moines 13
Jakarta 13
Wilmington 11
Atlanta 10
Munich 10
São Paulo 10
Milan 9
Rome 9
The Dalles 9
Tokyo 9
Warsaw 9
Curitiba 8
Mexico City 8
Nanjing 8
Brooklyn 7
Frankfurt am Main 7
Haiphong 7
Izmir 7
Montreal 7
Moscow 7
Pune 7
Toronto 7
Biên Hòa 6
Bologna 6
Changsha 6
Chicago 6
Houston 6
London 6
Quito 6
Rio de Janeiro 6
Amsterdam 5
Brussels 5
Helsinki 5
Nuremberg 5
Phoenix 5
Ankara 4
Belo Horizonte 4
Busseto 4
Can Tho 4
Cape Town 4
Denver 4
Dhaka 4
Guangzhou 4
Kunming 4
Nanchang 4
Naples 4
Orem 4
Pavia 4
Trieste 4
Washington 4
Baghdad 3
Boston 3
Buenos Aires 3
Florence 3
Francisco Morato 3
Fremont 3
Genoa 3
Grafing 3
Guayaquil 3
Hebei 3
Hải Dương 3
Istanbul 3
Jinan 3
Marseille 3
Nanning 3
Porto Alegre 3
Redondo Beach 3
Redwood City 3
Santiago 3
Shenyang 3
Sumaré 3
Thái Bình 3
Tirana 3
Totale 2.278
Salva come PNG Salva come JPEG
Nome #
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 191
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 179
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 162
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 161
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 154
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 153
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 151
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 138
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 138
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 137
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 129
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 129
Cystic brain metastases and RET fusion in lung cancer 126
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 121
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 121
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 119
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 118
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 116
Exploring the role of respiratory microbiome in lung cancer: A systematic review 114
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 110
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 106
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 98
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 97
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 91
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial 68
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 64
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 60
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis 58
ALK fusions turn sixteen in lung cancer: a review on their biology, detection and therapy 55
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 53
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 44
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P 31
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era 30
Non-small-cell lung cancer: how to manage BRAF-mutated disease 27
Totale 3.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.817
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.817
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022150 2 2 0 29 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024229 11 19 3 2 17 80 18 17 12 10 10 30
2024/2025645 6 30 35 47 99 94 25 12 88 57 49 103
2025/20261.786 132 91 215 166 298 120 172 65 226 129 103 69
Totale 3.649